| 영문 | Dilatation and Curettage(D & C) | 한글 | 자궁긁어냄술, 자궁목확장 |
|---|---|---|---|
| 설명 | 자궁이란 태아가 수태되어서 분만전까지 발육하고 성장하는 공간이다. 자궁속에 병변이 있어 임신이 계속될 수 없거나 아니면 다른 이유로 임신되어 있는 태아를 제거하고자 할 경우에 사용되는 방법이다. 여기서 긁어내기 위하여는 우선 자궁의 입구에 해당하는 자궁목을 확장시켜야 한다. 여기에는 급속히 확장을 시도하는 법과 서서히 확장을 시도하는 2가지 방법이 있다. 자궁목을 급속히 확장할 때는 헤가르 목관확장기(Hegar's dilatator)를 사용한다. 이것은 작은 금속막대로 작은 크기부터 큰 크기까지 다양한 크기가 있어서 우선 작은 막대로 시작하여 점점 큰 크기의 막대를 자궁목에 넣어서 자궁목을 확장시킨다. 서서히 확장시킬 때는 Laminaria tent를 목관에 삽입하는 방법을 사용한다. Laminaria tent란 해초로 만든 작은 막대로 수분을 흡수하면 점점 늘어나는 성질이 있다. 이것을 자궁의 목에 넣으면 이것이 수분을 흡수하여 늘어나므로 천천히 자궁의 목이 늘어난다. 자궁목이 충분히 늘어나면 그 속으로 끝이 숟가락처럼 생긴 기구를 넣어서 자궁속의 병변이나 임신된 태아를 긁어내는데 여기에 사용되는 숟가락처럼 생긴 기구를 큐렛이라고 한다. 초기 임신중절 즉 유산과 같은 임신과 관련된 경우뿐만 아니라, 비임신 자궁의 자궁내막조직의 채취 및 제거를 위해서도 행해지는 수기이다. 이는 원칙적으로 마취하에 실시되는 것으로 자궁목관을 확장하고 기구로 자궁 내용물을 제거하고 큐렛으로 자궁내벽을 깨끗이 한다. 자궁천공이나 자궁목의 파열 등의 위험이 따르며, 수술후 감염 또는 출혈 등에 대한 주의가 필요하다. |
||
| ICAAC | Interscience Conference on Antimicrobial Agents and Chemotherapy |
|---|---|
| IAP | immunosuppressive acidic protein; inosinic acid pyrophosphorylase; Institute of Animal Physiology; i... |
| IAS | immunosuppressive acidic substance; infant apnea syndrome; insulin autoimmune syndrome; interatrial ... |
| IM | idiopathic myelofibrosis; immunosuppressive method; implementation monitoring; Index Medicus; indome... |
| ISD | immunosuppressive drug; Information Services Division; inhibited sexual desire; interstimulus distan... |
| IS | Immunosuppressive |
|---|---|
| IAP | Immunosuppressive Acidic Protein |
| IAP | Immunosuppressive acid protein |
| IST | Immunosuppressive therapy |
| CWA | Chemical warfare agents |
cactus grandiflorus
acute angle
| antineoplastic and immunosuppressive agents | Collective grouping for substances used to arrest the proliferation of malignant cells and those that suppress the immune response. (12 Dec 1998) |
|---|
| immunosuppressive agents | Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of suppressor T-cell populations or by inhibiting the activation of helper cells. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of interleukins and other cytokines are emerging. (12 Dec 1998) |
|---|---|
| immunosuppressive | 1. Denoting or inducing immunosuppression. Synonym: immunosuppressant. (05 Mar 2000) |
| immunosuppressive agent | <immunology, pharmacology> Any chemotherapeutic agent which also has the effect of suppressing the immune system. most often these agents will reduce the absolute number of white blood cells in the bloodstream. (27 Sep 1997) |
| immunosuppressive drugs | Drugs that block the bodys ability to fight infection or foreign substances that enter the body. A person receiving an organ transplant is given these drugs to stop the body from rejecting the new organ or tissue. Cyclosporin is a commonly used immunosuppressive drug. (09 Oct 1997) |
| antibiotics, antineoplastic | Chemical substances, produced by microorganisms, inhibiting or preventing the development of neoplasms. (12 Dec 1998) |
| antimetabolites, antineoplastic | Antimetabolites that are useful in cancer chemotherapy. (12 Dec 1998) |
| antineoplastic | Inhibiting or preventing the development of neoplasms, checking the maturation and proliferation of malignant cells. Origin: Gr. Plassein = to form (18 Nov 1997) |
| antineoplastic agent | Agents inhibiting or preventing the growth of neoplasms, checking the maturation and proliferation of malignant cells. (12 Dec 1998) |
| antineoplastic agent, alkylating | A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumour efficacy and the presence in their chemical structures of n-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumour cells are not completely understood. (12 Dec 1998) |
| antineoplastic agent, combined | The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. (12 Dec 1998) |
| antineoplastic agent, hormonal | Antineoplastic agent that are used to treat hormone-sensitive tumours. Hormone-sensitive tumours may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumour regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumours may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukaemias. (12 Dec 1998) |
| antineoplastic agent, phytogenic | Agents, obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (12 Dec 1998) |
| antineoplastic drug | A drug that stops or slows the maturation and spread of tumour cells (benign or malignant). (09 Oct 1997) |
| anti-allergic and respiratory system agents | A collective term for drugs used to treat allergic reactions as well as those drugs that produce an effect on the respiratory system. (12 Dec 1998) |
| carbohydrates and hypoglycaemic agents | A collective term for carbohydrates and agents used to lower the level of glucose in the blood. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|